Evidence map›Paper›PMID 40369438›Full record

Trial reportBMC geriatrics2025

Comparison of the efficacy and safety of remimazolam and propofol for fiberoptic bronchoscopy in older patients: a prospective, randomized controlled study.

Binggao Chai, Jiaxi Guo, Zhiwei Xu, Tao Chen, Hongquan Wang, Zhenqiang Zhu, Jian Zhong, Kanzheng Chen, Jianlong Du, Xianhui Kang

Abstract readRandomized Controlled TrialComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC geriatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Binggao Chai *Department of Anesthesiology, Tongxiang First People's Hospital, Tongxiang, China.
Jiaxi Guo *Department of Anesthesiology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Zhiwei XuDepartment of Breast Surgery, Tongxiang First People's Hospital, Tongxiang, China.
Tao ChenDepartment of Anesthesiology, Tongxiang First People's Hospital, Tongxiang, China.
Hongquan WangDepartment of Respiratory Medicine, Tongxiang First People's Hospital, Tongxiang, China.
Zhenqiang ZhuDepartment of Anesthesiology, Tongxiang First People's Hospital, Tongxiang, China.
Jian ZhongDepartment of Anesthesiology, Tongxiang First People's Hospital, Tongxiang, China.
Kanzheng ChenDepartment of Respiratory Medicine, Tongxiang First People's Hospital, Tongxiang, China.
Jianlong DuDepartment of Anesthesiology, Tongxiang First People's Hospital, Tongxiang, China. 987268919@qq.com.
Xianhui KangDepartment of Anesthesiology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. kxhui66@zju.edu.cn.

Funding

Zhejiang Administration of Traditional Chinese Medicine 2024ZL1115Zhejiang Provincial Health Commission 2023KY341Zhejiang Provincial Health Commission 2024XY060
6 · The paper itself

Abstract

objectiveThe aim of this study was to compare the efficacy and safety of remimazolam with those of propofol in older patients undergoing fiberoptic bronchoscopy with preserved spontaneous breathing.

methodsSixty older patients were randomly and equally divided into a remimazolam group (group R) and a propofol group (group P). Both groups received 0.15 µg/kg of sufentanil for analgesia. Group R received an initial dose of 0.2 mg/kg remimazolam and was injected with a maintenance dose of 1 mg/kg/h. Group P received an initial dose of 2 mg/kg propofol and was injected with a maintenance dose of 4 mg/kg/h. The primary evaluation indicators were the success rate of sedation and the incidence of hypotension. The secondary evaluation indicators were respiratory depression, hypertension, tachycardia, bradycardia, awakening time, quality of recovery-15 (QOR-15) score, patient satisfaction, physician satisfaction, and adverse events.

resultsSuccess rates of sedation were similar between group R (96.7%) and group P (100%). The incidence of hypotension in group R was lower than that in group P (2/30 vs. 10/30, p = 0.01). Respiratory depression was lower in group R than in group P (3/30 vs. 10/30, p = 0.03). Fewer patients reported injection pain in group R (0/30 vs. 7/30, p = 0.01). There were no significant differences in hypertension, tachycardia, bradycardia, awakening time, QoR-15 score, patient satisfaction, physician satisfaction, or adverse events between the two groups.

conclusionsRemimazolam has a high sedation success rate for painless fiberoptic bronchoscopy in older patients, and the incidence of hypotension and respiratory depression is lower than that of propofol. Remimazolam may be a better choice for sedation during painless fiberoptic bronchoscopy in older patients with preserved spontaneous breathing.

trial registrationChiCTR2300069041; 6/3/2023.

Indexed as

BenzodiazepinesBronchoscopyFiber Optic TechnologyHypnotics and SedativesPropofolAgedAged, 80 and overAnesthetics, IntravenousFemaleHumansMaleProspective StudiesTreatment OutcomeAnesthetics, IntravenousBenzodiazepinesHypnotics and SedativesPropofolremimazolamAgedFiberoptic bronchoscopyPropofolRemimazolam

Identifiers

PMID40369438
PMCPMC12076816

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.